|
Balance Sheet Cash Flow Statement 2408 Timberloch Place, B-7 The Woodlands, TX 77380 TX Tel. 281-719-3400 Fax 281-719-3446 |
Type: Public
On the web:
http://www.reprosrx.com
Employees:
10
Employee growth: 42.9%
Repros Therapeutics (formerly Zonagen) zeroes in on reproductive health. The pharmaceutical firm develops small-molecule drugs to treat hormonal and reproductive system disorders. Its lead candidate, Proellex, was in clinical trials as a possible therapy for uterine fibroids (benign tumors within the uterus) and for anemia associated with uterine fibroids, but the company suspended Proellex trials in 2009 due to safety concerns. Repros' second candidate Androxal may treat testosterone deficiencies in men, particularly in relation to the drug's effects on fertility. The company is exploring strategic alternatives, including possible liquidation or bankruptcy.
Key numbers for fiscal year ending December, 2008:
Sales: $0.4M
One year growth: (71.3%)
Net income: ($25.2)M
Officers:
Chairman: Mark Lappe
CEO and Director: Joseph S. Podolski
President and Secretary: Paul Lammers
Competitors:
Abbott Labs
Solvay Pharmaceuticals
Watson Pharmaceuticals
